BACKGROUND: CRISPR/Cas9 gene editing strategies have revolutionized our ability to engineer the human genome for robust functional interrogation of complex biological processes. We have recently adapted this technology to primary human CD4+ T cells to generate a high-throughput platform for analyzing the role of host factors in HIV replication and pathogenesis. Unlike traditional RNA interference or complementation approaches, this technique generates permanent genetic changes to the host genome at high efficiency with only transient expression of the modifying agents. METHODS: CRISPR/Cas9 ribonucleoproteins (crRNPs) are synthesized in vitro and delivered to activated primary human CD4+ T cells by electroporation. These cells are then expanded and parsed out for validation, cryopreservation, and infection. Our platform supports the arrayed generation of hundreds of specific gene manipulations in only a few hours time and is widely adaptable to an array of culturing conditions, infection protocols, and downstream applications. RESULTS: We first used this platform to perform proof-of-principle experiments targeting host factors with defined roles in HIV replication. As expected, CXCR4 or CCR5 knock-out primary T cells are resistant to HIV infection in a tropism-dependent manner, whereas knock-out of LEDGF or TNPO3 results in a tropism-independent reduction in infection. We next bridged this approach to other proteomic and genomic discovery platforms as a secondary screen for host factor functionality, identifying several candidate dependency and restriction factors for additional mechanistic study. Finally, we found that crRNP multiplexing allows for the editing of multiple genes simultaneously, enabling studies of functional redundancy or epistasis among multiple host and viral factors. CONCLUSIONS: This technology should prove useful for not only discovery-based scientific research, but may additionally accelerate target validation for pharmaceutical and cell-based therapies to cure HIV infection. We are currently adapting this technology to achieve efficient genome editing at the level of a single base pair, as well as adapting it to other primary cell types for the study of additional biological processes and disease states. Recent advances with CRISPR interference, CRISPR activation, BaseEditor technology, high-fidelity Cas9 enzymes, and Cas9 inhibitors will also be discussed.